Therapeutic doses of phenylpropanolamine increase supine systolic blood pressure
- PMID: 4030197
Therapeutic doses of phenylpropanolamine increase supine systolic blood pressure
Abstract
The anorectic agent phenylpropanolamine (PPA) has a low therapeutic index and can cause severe hypertension at doses as low as 85 mg. To determine the effects of a therapeutic dose on blood pressure, PPA 37.5 mg (as a commercially available immediate release formulation) or placebo was administered orally to ten normotensive subjects using a randomized double-blinded crossover design. The mean increase in supine systolic blood pressure (BP) was greater after PPA (18.5 +/- 10.7 mmHg) than after placebo (5.1 +/- 5.4 mmHg, P = 0.005). Increases in systolic BP after PPA ranged from 8 to 43 mmHg. The BP increase due to PPA was postural, and there was no change in sitting or standing BP. Doses of PPA available in over-the-counter formulations can increase supine systolic BP. Recent use of products containing PPA should be considered when evaluating patients with hypertension.
Similar articles
-
The effect of phenylpropanolamine on blood pressure during upright bicycle exercise in normal subjects.Int J Obes. 1989;13(4):505-10. Int J Obes. 1989. PMID: 2676877 Clinical Trial.
-
Effects of phenylpropanolamine and isometric exercise on blood pressure.Int J Obes. 1988;12(3):199-204. Int J Obes. 1988. PMID: 3391736 Clinical Trial.
-
Transient hypertension after two phenylpropanolamine diet aids and the effects of caffeine: a placebo-controlled follow-up study.Am J Med. 1989 Apr;86(4):427-32. doi: 10.1016/0002-9343(89)90341-0. Am J Med. 1989. PMID: 2929629 Clinical Trial.
-
Psychiatric side effects attributed to phenylpropanolamine.Pharmacopsychiatry. 1988 Jul;21(4):171-81. doi: 10.1055/s-2007-1014671. Pharmacopsychiatry. 1988. PMID: 3060884 Review.
-
Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports.Am J Med. 1990 Aug;89(2):195-208. doi: 10.1016/0002-9343(90)90299-s. Am J Med. 1990. PMID: 2200264 Review.
Cited by
-
Safety of drug therapies used for weight loss and treatment of obesity.Drug Saf. 2006;29(4):277-302. doi: 10.2165/00002018-200629040-00001. Drug Saf. 2006. PMID: 16569079 Review.
-
Non-prescription sympathomimetic agents and hypertension.Med Toxicol Adverse Drug Exp. 1988 Sep-Oct;3(5):387-417. doi: 10.1007/BF03259892. Med Toxicol Adverse Drug Exp. 1988. PMID: 3057328 Review.
-
Drug interactions in hypertensive patients. Pharmacokinetic, pharmacodynamic and genetic considerations.Clin Pharmacokinet. 1990 Apr;18(4):295-317. doi: 10.2165/00003088-199018040-00003. Clin Pharmacokinet. 1990. PMID: 2182265 Review.
-
The effects of urine pH modification on the pharmacokinetics and pharmacodynamics of phenylpropanolamine.Pharm Res. 1990 Jan;7(1):96-102. doi: 10.1023/a:1015852012968. Pharm Res. 1990. PMID: 2300545 Clinical Trial.